Anzeige
Mehr »
Login
Donnerstag, 04.03.2021 Börsentäglich über 12.000 News von 657 internationalen Medien
Übernahme-News! Relay Medical im Fokus der Anleger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AQDY ISIN: US05502L1052 Ticker-Symbol: 366 
Tradegate
03.03.21
18:19 Uhr
1,160 Euro
+0,010
+0,87 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
AZURRX BIOPHARMA INC Chart 1 Jahr
5-Tage-Chart
AZURRX BIOPHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,0401,12008:09
1,0601,10008:09

Aktuelle News zur AZURRX BIOPHARMA Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiAzurRx BioPharma, Inc.: AzurRx BioPharma to Participate in "Fireside Chat" at the H.C. Wainwright Global Life Sciences Conference2
25.02.AzurRx BioPharma, Inc. - 8-K, Current Report5
24.02.AzurRx BioPharma, Inc.: AzurRx BioPharma Appoints President and CEO James Sapirstein as New Chairman of the Board of Directors3
AZURRX BIOPHARMA Aktie jetzt für 0€ handeln
16.02.AzurRx BioPharma, Inc. - 8-K, Current Report4
16.02.AzurRx BioPharma, Inc.: AzurRx BioPharma to Present at The Microcap Rodeo Winter Wonderland Conference6
10.02.Why AzurRx BioPharma, Usana Health Are Moving Today10
09.02.AzurRx BioPharma jumps 18% over formulation trial for treatment of COVID-19-associated gastrointestinal infections11
09.02.AzurRx BioPharma, Inc.: AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections6
31.01.AzurRx Officially A COVID-19 Play - The Right Dose For Your Portfolio19
29.01.NVAX's Covid Jab Shows 89.3% Efficacy In UK Trial, AZRX Awaits Data, FDA Lifts Hold On BLCM Trial368BEIJING (dpa-AFX) - Today's Daily Dose brings you news about encouraging results of Novavax' Covid-19 vaccine candidate; FDA lifting the clinical hold on Bellicum's BPX-601 study; and near-term...
► Artikel lesen
28.01.AzurRx Bio completes enrollment in first cohort of mid-stage study of MS1819, shares up 13%4
28.01.AzurRx BioPharma, Inc.: AzurRx BioPharma Announces Completion of Enrollment in First Cohort of Phase 2b OPTION 2 Extension Study of MS18192
26.01.AzurRx adds two new trial sites in Europe for phase 2b OPTION 2 extension study4
22.01.Why AzurRx BioPharma Is Trading Sharply Higher Today35
22.01.Adamis Pharmaceuticals, AzurRx BioPharma leads healthcare gainers; Celsion, ViewRay among major losers46
22.01.AzurRx (AZRX) Starts Dosing in Pancreatic Insufficiency Study21
21.01.AzurRx starts dosing in mid-stage cystic fibrosis study of MS181926
15.01.AzurRx BioPharma, Inc. - 8-K, Current Report8
13.01.AzurRx BioPharma, Inc. - S-1, General form for registration of securities4
12.01.AzurRx BioPharma, Inc.: AzurRx BioPharma and First Wave Bio Announce Allowance of U.S. Patent Application for Niclosamide as Treatment for COVID-19 Gastrointestinal ...20
Seite:  Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
2,1,6